Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological...
$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants
$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants
Patent provides added depth to Enveric’s EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions
Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements...
Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc.
As a result of this action, there are no remaining challenges currently pending against Enveric’s patent
Proprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT₂ A , pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects ...
RCANN ™ Trademark Portfolio Out-Licensed